Related Experiment Video
Updated: Aug 5, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Light Transmission Aggregometry Versus VerifyNow for Antiplatelet Monitoring in Flow Diversion: A Retrospective
Andrey Petrov1,2,3, Sergei Ermakov1,2,4, Alexey Kornev4
1Vascular Neurosurgery Department, Polenov Neurosurgical Research Institute, Branch of Almazov National Medical Research Centre, 191014 Saint Petersburg, Russia.
Diagnostics (Basel, Switzerland)
|July 28, 2026
Summary
Light transmission aggregometry (LTA) may help monitor antiplatelet therapy (APT) during flow diversion for intracranial aneurysms. Lower platelet reactivity showed fewer complications, but more research is needed to confirm thresholds.
Area of Science:
- Neuroendovascular surgery
- Interventional neuroradiology
- Cardiology/Hematology
Background:
- Flow diversion stents (FDS) are increasingly used for intracranial aneurysms (IA).
- Optimal antiplatelet therapy (APT) regimens for FDS are not well-defined.
- Monitoring APT effectiveness is crucial to prevent complications.
Purpose of the Study:
- To evaluate light transmission aggregometry (LTA) for routine APT monitoring during FDS.
- To assess if LTA-derived residual platelet reactivity correlates with thromboembolic complications.
- To compare LTA with VerifyNow (VN) P2Y12 reaction units (PRU) for method agreement.
Main Methods:
- Retrospective analysis of 203 intracranial aneurysm patients treated with FDS and LTA-guided APT.
- LTA used for all patients; VerifyNow (VN) P2Y12 testing in a subset of 84 patients.
- Primary outcome: thromboembolic complications (TECs); Secondary outcome: intracranial hemorrhage.
Main Results:
- High aneurysm occlusion rate (83.7%) and favorable functional outcomes (97.5% mRS ≤ 2) at 12 months.
- Low rates of TECs (3.4%) and hemorrhagic complications (2.0%) observed.
- LTA and VN showed moderate correlation and wide agreement limits, indicating non-interchangeability.
Conclusions:
- Routine LTA may be useful for monitoring APT in FDS procedures.
- Lower LTA-measured platelet reactivity was associated with fewer adverse events, but findings are exploratory.
- Further large-scale studies are required to establish definitive APT thresholds for FDS.
